Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of C-CAR011 in Relapsed/Refractory B-cell NHL
NCT03154775Phase 1Unknown
- Sponsor
- AbelZeta
- Start
- May 2017
- Primary completion
- Apr 2018
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of C-CAR011 in B-cell non-Hodgkin lymphoma, sponsored by AbelZeta. Primary endpoints: Incidence of adverse events at 12 weeks and Objective Response Rate at 12 weeks. Status: unknown.
02
Drugs
C-CAR011
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03154775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03154775.